Johnson & Johnson operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Johnson & Johnson with three other
major healthcare and pharmaceutical companies:
Bristol-Myers Squibb Company
sales of $26.15 billion
of which 30%
was Prioritized Brands-Eliquis),
Baxter International Inc.
of which 54%
was Americas), and
based in SWITZERLAND
(48.29 billion Swiss Francs [US$51.43 billion]
of which 78%
was Innovative Medicines).
During the year ended December of 2019, sales at
Johnson & Johnson were $82.06 billion.
a very small
increase of 0.6%
versus 2018, when the company's sales were $81.58 billion.
This was the fourth straight year of sales growth at Johnson & Johnson.
Sales of Pharmaceutical saw an increase
that was more than double the company's growth rate: sales were up
3.6% in 2019, from
$40.73 billion to $42.20 billion.
Not all segments of Johnson & Johnson experienced an increase in sales in 2019:
sales of Medical Devices fell 3.8% to $25.96 billion.